Allogene Therapeutics (ALLO) EBIT (2018 - 2026)

Allogene Therapeutics has disclosed EBIT across 9 years of filings, most recently posting -$46.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$46.1 million, up 29.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$190.2 million (up 29.26% YoY), and the FY2025 annual result was -$209.3 million, up 23.38% from the prior year.
• EBIT came in at -$46.1 million for Q1 2026 at Allogene Therapeutics, down from -$42.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$42.4 million in Q4 2025 to a low of -$99.1 million in Q1 2023.
• The 5-year median for EBIT is -$71.4 million (2024), against an average of -$70.1 million.
• Across the five-year window, EBIT slumped 5747.04% in 2022 and jumped 37.44% in 2025, its largest moves.
• Allogene Therapeutics' EBIT stood at -$96.4 million in 2022, then gained by 11.71% to -$85.1 million in 2023, then climbed by 28.93% to -$60.5 million in 2024, then climbed by 29.9% to -$42.4 million in 2025, then retreated by 8.7% to -$46.1 million in 2026.
• The last three EBIT figures came in at -$46.1 million (Q1 2026), -$42.4 million (Q4 2025), and -$44.9 million (Q3 2025), per Business Quant data.